JEFFERSON CITY, MO – Missouri will receive part of a fraud settlement against pharmaceutical company Mylan.

The case alleged that from July 2010 until March 2017, Mylan submitted false statements to the Centers for Medicare and Medicaid Services regarding the classification of EpiPen.

Epi-pen had been classified as a non-innovator multiple source instead of a single source or innovator multiple source. A single source drug is a drug that was originally marketed as an original new drug while non-innovator drugs are not marketed as an original new drug.

Accordingly, Mylan did not submit a best price for the EpiPen resulting in underpayment in its rebates to State Medicaid programs. According to Missouri Attorney General, Josh Hawley, the settlement in Missouri amounts to over $3.1 million.